Broncho-Vaxom® was pigeonholed as a "niche prophylactic"—seen as ineffective once symptoms appeared and limited to bacterial prevention. This perception capped market share and stalled growth against direct competitors.

We pivoted from a product feature narrative to a high-stakes clinical reality:

• Reframed the risk: shifted the focus to at-risk patients, demonstrating how minor RTIs rapidly escalate into life-threatening complications.

• The "Triple Action" framework: repositioned the drug as a comprehensive immune modulator that tackles both viral and bacterial threats while reducing airway inflammation.

• Expanded clinical utility: broke the prevention-only barrier by validating its use as a concomitant treatment during active infections.

By transforming the brand from a "preventative extra" to an essential intervention, we dismantled prescription barriers and expanded the drug’s role across the entire infection cycle.